|
1
|
Salah S, Ahmad R, Sultan I, Yaser S and
Shehadeh A: Osteosarcoma with metastasis at initial diagnosis:
Current outcomes and prognostic factors in the context of a
comprehensive cancer center. Mol Clin Oncol. 2:811–816.
2014.PubMed/NCBI
|
|
2
|
Jawad MU, Cheung MC, Clarke J, Koniaris LG
and Scully SP: Osteosarcoma: Improvement in survival limited to
high-grade patients only. J Cancer Res Clin Oncol. 137:597–607.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mialou V, Philip T, Kalifa C, Perol D,
Gentet JC, Marec-Berard P, Pacquement H, Chastagner P, Defaschelles
AS and Hartmann O: Metastatic osteosarcoma at diagnosis: Prognostic
factors and long-term outcome-the French pediatric experience.
Cancer. 104:1100–1109. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hegyi M, Semsei AF, Jakab Z, Antal I, Kiss
J, Szendroi M, Csoka M and Kovacs G: Good prognosis of localized
osteosarcoma in young patients treated with limb-salvage surgery
and chemotherapy. Pediatr Blood Cancer. 57:415–422. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hess D and Igal RA: Genistein
downregulates de novo lipid synthesis and impairs cell
proliferation in human lung cancer cells. Exp Biol Med (Maywood).
236:707–713. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alo PL, Amini M, Piro F, Pizzuti L,
Sebastiani V, Botti C, Murari R, Zotti G and Di Tondo U:
Immunohistochemical expression and prognostic significance of fatty
acid synthase in pancreatic carcinoma. Anticancer Res.
27:2523–2527. 2007.PubMed/NCBI
|
|
7
|
Walter K, Hong SM, Nyhan S, Canto M,
Fedarko N, Klein A, Griffith M, Omura N, Medghalchi S, Kuhajda F
and Goggins M: Serum fatty acid synthase as a marker of pancreatic
neoplasia. Cancer Epidemiol Biomarkers Prev. 18:2380–2385. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Migita T, Ruiz S, Fornari A, Fiorentino M,
Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E,
et al: Fatty acid synthase: A metabolic enzyme and candidate
oncogene in prostate cancer. J Natl Cancer Inst. 101:519–532. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Silva SD, Cunha IW, Younes RN, Soares FA,
Kowalski LP and Graner E: ErbB receptors and fatty acid synthase
expression in aggressive head and neck squamous cell carcinomas.
Oral Dis. 16:774–780. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saati GE and Archer MC: Inhibition of
Fatty Acid synthase and sp1 expression 3-3′-diindolylmethane in
human breast cancer cells. Nutr Cancer. 63:790–794. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Notarnicola M, Pisanti S, Tutino V, Bocale
D, Rotelli MT, Gentile A, Memeo V, Bifulco M, Perri E and Caruso
MG: Effects of olive oil polyphenols on fatty acid synthase gene
expression and activity in human colorectal cancer cells. Genes
Nutr. 6:63–69. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Notarnicola M, Messa C, Refolo MG, Tutino
V, Miccolis A and Caruso MG: Polyunsaturated fatty acids reduce
fatty acid synthase and hydroxy-methyl-glutaryl CoA-reductase gene
expression and promote apoptosis in HepG2 cell line. Lipids Health
Dis. 10:102011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zecchin KG, Rossato FA, Raposo HF, Melo
DR, Alberici LC, Oliverira HC, Castilho RF, Coletta RD, Vercesi AE
and Graner E: Inhibition of fatty acid synthase in melanoma cells
activates the intrinsic pathway of apoptosis. Lab Invest.
91:232–240. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Murata S, Yanagisawa K, Fukunaga K, Oda T,
Kobayashi A, Sasaki R and Ohkohchi N: Fatty acid synthase inhibitor
cerulenin suppresses liver metastasis of colon cancer in mice.
Cancer Sci. 101:1861–1865. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu ZL, Wang G, Peng AF, Luo QF, Zhou Y
and Huang SH: Fatty acid synthase expression in osteosarcoma and
its correlation with pulmonary metastasis. Oncol Lett. 4:878–882.
2012.PubMed/NCBI
|
|
16
|
Wang TF, Wang H, Peng AF, Luo QF, Liu ZL,
Zhou RP, Gao S, Zhou Y and Chen WZ: Inhibition of fatty acid
synthase suppresses U-2 OS cell invasion and migration via
downregulating the activity of HER2/PI3K/AKT signaling pathway in
vitro. Biochem Biophys Res Commun. 440:229–234. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment - Where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang R, Zheng J, Zhang DS, Yang YH and
Zhao ZF: Wnt1-induced MAFK expression promotes osteosarcoma cell
proliferation. Genet Mol Res. 14:7315–7325. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao S, Kurenbekova L, Gao Y, Roos A,
Creighton CJ, Rao P, Hicks J, Man TK, Lau C, Brown AM, et al: NKD2,
a negative regulator of Wnt signaling, suppresses tumor growth and
metastasis in osteosarcoma. Oncogene. 34:5069–5079. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gupte A, Baker EK, Wan SS, Stewart E, Loh
A, Shelat AA, Gould CM, Chalk AM, Taylor S, Lackovic K, et al:
Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a
conserved therapeutic vulnerability in osteosarcoma. Clin Cancer
Res. 21:3216–3229. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tao J, Jiang MM, Jiang L, Salvo JS, Zeng
HC, Dawson B, Bertin TK, Rao PH, Chen R, Donehower LA, et al: Notch
activation as a driver of osteogenic sarcoma. Cancer Cell.
26:390–401. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Uemoto Y, Abe T, Tameoka N, Hasebe H,
Inoue K, Nakajima H, Shoji N, Kobayashi M and Kobayashi E:
Whole-genome association study for fatty acid composition of oleic
acid in Japanese Black cattle. Anim Genet. 42:141–148. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kuhajda FP: Fatty acid synthase and
cancer: New application of an old pathway. Cancer Res.
66:5977–5980. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zaytseva YY, Harris JW, Mitov MI, Kim JT,
Butterfield DA, Lee EY, Weiss HL, Gao T and Evers BM: Increased
expression of fatty acid synthase provides a survival advantage to
colorectal cancer cells via upregulation of cellular respiration.
Oncotarget. 6:18891–19904. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bauerschlag DO, Maass N, Leonhardt P,
Verburg FA, Pecks U, Zeppernick F, Morgenroth A, Mottaghy FM, Tolba
R, Meinhold-Heerlein I and Bräutigam K: Fatty acid synthase
overexpression: Target for therapy and reversal of chemoresistance
in ovarian cancer. J Transl Med. 13:1462015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hamada S, Horiguchi A, Kuroda K, Ito K,
Asano T, Miyai K and Iwaya K: Elevated fatty acid synthase
expression in prostate needle biopsy cores predicts upgraded
Gleason score in radical prostatectomy specimens. Prostate.
74:90–96. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Porta R, Blancafort A, Casòliva G, Casas
M, Dorca J, Buxo M, Viñas G, Oliveras G and Puig T: Fatty acid
synthase expression is strongly related to menopause in early-stage
breast cancer patients. Menopause. 21:188–191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Agostini M, Almeida LY, Bastos DC, Ortega
RM, Moreira FS, Seguin F, Zecchin KG, Raposo HF, Oliveira HC,
Amoêdo ND, et al: The fatty acid synthase inhibitor orlistat
reduces the growth and metastasis of orthotopic tongueoral squamous
cell carcinomas. Mol Cancer Ther. 13:585–595. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Seguin F, Carvalho MA, Bastos DC, Agostini
M, Zecchin KG, Alvarez-Flores MP, Chudzinski-Tavassi AM, Coletta RD
and Graner E: The fatty acid synthase inhibitor orlistat reduces
experimental metastases and angiogenesis in B16-F10 melanomas. Br J
Cancer. 107:977–987. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu ZL, Mao JH, Peng AF, Yin QS, Zhou Y,
Long XH and Huang SH: Inhibition of fatty acid synthase suppresses
osteosarcoma cell invasion and migration via downregulation of the
PI3K/Akt signaling pathway in vitro. Mol Med Rep. 7:608–612.
2013.PubMed/NCBI
|
|
32
|
Liu ZL, Zhou Y, Luo QF, Hu M, Wang G,
Huang SH and Shu Y: Inhibition of fatty acid synthase supresses
osteosarcoma cell invasion and migration. Indian J Pathol
Microbiol. 55:163–169. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dong Y, Liang G, Yuan B, Yang C, Gao R and
Zhou X: MALAT1 promotes the proliferation and metastasis of
osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol.
36:1477–1486. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tomek K, Wagner R, Varga F, Singer CF,
Karlic H and Grunt TW: Blockade of fatty acid synthase induces
ubiquitination and degradation of phosphoinositide-3-kinase
signaling proteins in ovarian cancer. Mol Cancer Res. 9:1767–1779.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Puig T, Turrado C, Benhamú B, Aguilar H,
Relat J, Ortega-Gutiérrez S, Casals G, Marrero PF, Urruticoechea A,
Haro D, et al: Novel inhibitors of fatty acid synthase with
anticancer activity. Clin Cancer Res. 15:7608–7615. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jiang B, Li EH, Lu YY, Jiang Q, Cui D,
Jing YF and Xia SJ: Inhibition of fatty-acid synthase suppresses
P-AKT and induces apoptosis in bladder cancer. Urology. 80:484.
e9–15. 2012. View Article : Google Scholar
|
|
37
|
Li N, Lu H, Chen C, Bu X and Huang P: Loss
of fatty acid synthase inhibits the ‘HER2-PI3K/Akt axis’ activity
and malignant phenotype of Caco-2 cells. Lipids Health Dis.
12:832013. View Article : Google Scholar : PubMed/NCBI
|
